Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. A phase II study (Pediatric Oncology Group).
CHIP (325 mg/M2), a second generation cisplatin derivative, was administered intravenously every 3 weeks to 85 pediatric patients with recurrent sarcomas (19), osteosarcomas (20), neuroblastoma (23), germ cell tumors (10), and other malignant tumors (7). Thirty-eight of them had been previously exposed to cisplatin. Partial remissions were only observed in 3 of 23 (13% SE = 7%) patients having neuroblastoma. Severe thrombocytopenia (65%) and neutropenia (35%) were the dose limiting factors.
Nitschke
R
R
Oklahoma Health Sciences Center, Oklahoma City.
Pratt
C
C
Harris
M
M
Krischer
J
J
Vietti
T J
TJ
Grier
H
H
Kamps
W
W
Toledano
S
S
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004341:Drug Evaluation; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy; D009447:Neuroblastoma / Q000188:drug therapy; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D012008:Recurrence; D012509:Sarcoma / Q000188:drug therapy; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C023359:iproplatin